fy

Z-FY-CHO (Z-Phe-Tyr-CHO) is a selective histone L (Cat L) inhibitor that promotes autophagy, reduces the accumulation of P62, and blocks the activation of caspase-3 and PARP.

FY-21 is a selective LSD1 inhibitor (IC50= 340 nM) that inhibits proliferation and colony formation of leukemia cells, decreases mRNA levels of the transcription factors HOXA9 and MEIS1, and can be used in the study of leukemia.

FY-56, a highly potent and selective inhibitor of LSD1/KDM1A with an IC50 value of 42 nM, demonstrates significant selectivity over MAO-A/B. This compound effectively induces differentiation in MOLM-13 and MV4-11 cells, showing promise for acute myeloid leukemia (AML) research [1].

FY26 is a potent Os(II) anticancer drug candidate, exerts its activity by generating reactive oxygen species and disrupting the redox balance in cancer cells Coadministration of FY26 and nontoxic doses of L-BSO allows the potentiation of its anticancer ac

Anti-Fy3 Antibody (MIMA-29) is a mouse IgG2a, κ chimeric antibody that targets human Fy3. The recommended isotype control for this antibody is Mouse IgG2a kappa, Isotype Control.

(±)-Tazifylline is a selective and long-acting antagonist of histamine H1 receptor. Tazifylline shows much lower affinity for H2 receptors, α- and β-adrenoceptors, 5-hydroxytryptamine and muscarinic receptor subtypes.

Tonapofylline is an orally active and selective antagonist of the A1 adenosine receptor (Ki: 7.4 nM for human A1). Tonapofylline can be used in studies about heart failure.

Propentofylline (Hextol) is a methylxanthine derivative with neuroprotective, antiproliferative, and anti-inflammatory activity and enhanced synaptic adenosine signaling, which may be useful in the study of Alzheimer's disease, vascular dementia, cognitive impairment, dementia, and chronic pain.

(R)-Lisofylline ((R)-Lisophylline) is an inhibitor of lysophosphatidic acid acyltransferase (IC50 = 0.6 µM) that interrupts IL-12 signaling-mediated STAT4 activation, making it useful for studies on the treatment of type 1 diabetes and autoimmune disorders.

(±)-Lisofylline is an enantiomer-specific, alkyl-substituted methylxanthine, which has specific and potent activity in down-regulating leukocyte activation. (±)-Lisofylline is an anti-inflammatory agent.

(S)-Lisofylline is the inactive optical enantiomer of (R)-lisofylline which is an anti-inflammatory agent. (S)-Lisofylline is exclusively converted to pentoxifylline in human liver microsomes.

(Rac)-Naxifylline may be used to study congestive heart failure.

Verofylline (Verofyllinum) is an orally available, long-acting, multiacting, methylxanthine-substituted bronchodilator with inhibitory effects on PDE4 for the treatment of asthma disease research obesity.

Torbafylline, a xanthine derivative, is a phosphodiesterase (PDE) inhibitor that attenuates burn-induced protein hydrolysis in rat skeletal muscle through activation of the PDE4/cAMP/EPAC/PI3K/Akt pathway, and inhibits the enhanced ubiquitin-proteasome-dependent protein hydrolysis in skeletal muscle of cancer- and sepsis-prone rats.

Laprafylline is a xanthine compound with inhibitory effects on bronchoconstriction in vivo and antitumor activity.Laprafylline acts as a competitive serotonergic antagonist at low concentrations, and inhibits constriction induced by hist at high difficulties.

Stacofylline is a xanthine derivative that is used to treat migraine headaches.

Pentoxifylline (PTX) modulates immunologic activity by stimulating cytokine production. Pentoxifylline is a methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It also inhibits platelet aggregation and improves blood flow by increasing erythrocyte and leukocyte flexibility.

Doxofylline (Doxophylline) is a methylxanthine derivative with the presence of a dioxolane group in position 7. As a drug used in the treatment of asthma, doxofylline has shown similar efficacy to theophylline but with significantly fewer side effects in animal and human studies.

Etofylline (Oxyphylline) is used for difficulty in breathing, asthma, breathing difficulty and other conditions.

Acefylline (Theophylline-7-acetic acid), a stimulant drug of the xanthine chemical class, acts as an adenosine receptor antagonist. It is combined with diphenhydramine in the pharmaceutical preparation Etanautine to help offset its stimulant effects

Istradefylline (KW-6002)(Ki of 2.2 nM) is a selective adenosine A2A receptor (A2AR) antagonist, which is under development in Phase 3 trails. It has been used in trials studying the treatment and basic science of Drug Abuse, Sleep Disorder, Hepatic Impairment, Parkinson's Disease, and Restless Legs Syndrome, among others.

HFY-4A HCL is a novel HDAC inhibitor.HFY-4A HCL has antitumour activity and has shown antiproliferative activity in breast cancer cells.

4-Desmethyl Istradefylline is a Istradefylline metabolite. Istradefylline is a very potent, selective, and orally active adenosine A2A receptor antagonist with Ki of 2.2 nM in experimental models of Parkinson's disease.

Spirofylline is an agent of bronchodilator, has the potential for asthma and bronchitis and emphysema treatment.